Review

rac1 (Proteintech)

Proteintech is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Proteintech rac1
Rac1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 183 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+rac1/Rac1+Antibody/pm41906249-54-20-37
Average 96 stars, based on 183 article reviews

rac1 - by Bioz Stars, 2026-09

96/100 stars

Images

Western Blot:

Article Title: Protein arginine methyltransferase 1 stimulates basal cell proliferation and migration to maintain corneal epithelial homeostasis
Article Snippet: Antibodies for immunofluorescence staining include anti-K12 (ab185627, Abcam), anti-K14 (10143-1-AP, Proteintech), anti-Ki67 (ab279653, Abcam), anti-pH3 (06-570, Millipore), anti-DCS2 (13876-1-AP, Proteintech), Alexa FluorTM 568 donkey anti-mouse IgG (H + L) (A10037, Invitrogen), Alexa FluorTM 488 donkey anti-mouse IgG (H + L) (A21202, Invitrogen), Alexa FluorTM 568 donkey anti-rabbit IgG (H + L) (A10042, Invitrogen), Alexa FluorTM 488 donkey anti-rabbit IgG (H + L) (A21206, Invitrogen), and Alexa FluorTM 647 donkey anti-mouse IgG (H + L) (A31571, Invitrogen). .. Antibodies for immunoblotting include anti-PRMT1 (2449S, Cell Signaling Technology), anti-β-actin (AC026, ABclonal), anti-GFP (ab0005, Abways), anti-MAP4(11229-1-AP, Proteintech), anti-VCL (ab18058, Abcam), anti-CDK9 (11705-1-AP, Proteintech), anti-MMA (#8015, Cell Signaling Technology), anti-ADMA (#13522, Cell Signaling Technology), anti-CFL1(10960-1-AP, Proteintech), anti-MAPK2 (11257-1-AP, Proteintech), anti-RAC1 (24072-1-AP, Proteintech), and anti-RHOA (10749-1-AP, Proteintech). ..

Article Title: Interactive effects of Bisphenol F exposure and TLR4 rs4986790 on unexplained miscarriage
Article Snippet: PVDF membranes were blocked with 5% bovine serum albumin (BSA; Sigma Aldrich, USA) at room temperature for 1 h and then incubated with primary antibodies overnight at 4 °C. .. Primary antibodies included anti-TLR4 (1:1000, #38519, CST, USA, RRID: AB_2924306 , exclusively for Western blotting of TLR4 protein in women villous tissues and human trophoblast cells), anti-MMP9 (1:1000, R380831, ZEN-BIOSCIENCE, China, RRID: AB_3712851 ), anti-RAC1 (1:1000, 66122-1-Ig, Proteintech, USA, RRID: AB_2881521 ), anti-β2GPI (1:1000, #389197, ZEN-BIOSCIENCE, China, RRID: AB_3712853 ), anti-FOXP3 (1:1000, A4953, Abclonal, RRID: AB_2863396 ), anti-GAPDH (1:10000, ab8245, Abcam, UK, RRID: AB_2107448 ), anti-Tubulin (dilution 1:10000, 66240, Proteintech, USA, RRID: AB_2881629 ), and anti-NA/K-ATPase A1 (1:10000, ab76020, Abcam, UK, RRID: AB_1310695 ). ..

Article Title: Interactive effects of Bisphenol F exposure and TLR4 rs4986790 on unexplained miscarriage.
Article Snippet: PVDF membranes were blocked with 5% bovine serum albumin (BSA; Sigma Aldrich, USA) at room temperature for 1 h and then incubated with primary antibodies overnight at 4 ◦C. .. Primary antibodies included anti-TLR4 (1:1000, #38519, CST, USA, RRID: AB_2924306, exclusively for Western blotting of TLR4 protein in women villous tissues and human trophoblast cells), anti-MMP9 (1:1000, R380831, ZENBIOSCIENCE, China, RRID: AB_3712851), anti-RAC1 (1:1000, 66122-1-Ig, Proteintech, USA, RRID:AB_ 2881521), anti-β2GPI (1:1000, #389197, ZENBIOSCIENCE, China, RRID: AB_3712853), antiFOXP3 (1:1000, A4953, Abclonal, RRID:AB_2863396), anti-GAPDH (1:10000, ab8245, Abcam, UK, RRID:AB_ 2107448), anti-Tubulin (dilution 1:10000, 66240, Proteintech, USA, RRID:AB_2881629), and anti-NA/KATPase A1 (1:10000, ab76020, Abcam, UK, RRID:AB_ 1310695). ..

Saline:

Article Title: C1QL1 regulates auditory nerve fibers growth via ELMO1-DOCK180-RAC1 integrin.
Article Snippet: Background: complement c1q like 1 (c1Ql1), a secreted protein, is known to play an important role in synaptic maturation, regulation, and maintenance in central nervous system. c1Ql1 is expressed in adult cochlea inner and outer hair cells. however, the mechanism of c1Ql1 in cochlea remains unclear.. Objective: this study aims to reveal the mechanism of C1ql1 gene in cochlea, including its target and pathway.. Material and Methods: the protein-protein interaction analysis of c1Ql1 was conducted with stRiNG database. the interaction between c1Ql1 and Bai3 in cochlea was further confirmed by colocalization and co-immunoprecipitation. via upregulating and downregulating the expression of C1ql1, the factors in the pathway can be detected.

Incubation:

Image Search Results

A Gene set enrichment analysis on Fast-growing compared to parental cells ( n = 288 genes) and Endocrine Tolerant resistant cells compared to parental cells ( n = 288 genes) using Curated.MSigDB. B / C Steiner Forest signalling network analysis in upregulated genes ( n = 288) of B Fast-growing and C Endocrine Tolerant cells. Node size indicates number of attached edges, with nodes with >8 in bold. Node colours: Brown=genes, light blue=phenotype, dark blue=protein complex, pink=protein family. D Multiplexed analysis of EGFR phosphorylation in: basal cells, 30 min 100 ng/mL EGF, 30 min 100 nM 17 β-estradiol, or 30 min serum stimulation. Analysed by two-way ANOVA with Bonferroni’s multiple comparison test from n = 3 biological replicates, error bars=SD. E Western blot of EGFR, pEGFR (Y1045) and β-actin in Fast and Endocrine Tolerant cells after 100 ng/mL EGF treatment for indicated times, representative of 3 biological replicates. F Multiplexed analysis of HER2 phosphorylation following treatment described in D . Analysed by two-way ANOVA with Bonferroni’s multiple comparison test. G Western blot of HER2, pHER2 (Y1221/1222) and β-actin in Fast and Endocrine Tolerant cells after 100 ng/mL EGF stimulation for indicated times, representative of 3 biological replicates. (H) PREX1 transcripts from scRNAseq analysis of MCF-7 cells treated for 48 hours with fulvestrant ( n = 340 cells), and in Fast-growing ( n = 578 cells) and Endocrine Tolerant ( n = 659 cells). I Western blot of P-Rex1, Rac1, Pak2 and β-actin in Fast and Endocrine Tolerant cells, representative of 3 biological replicates. J Densitometry of P-Rex1 normalised to β-actin from n = 3 biological replicates. Analysed by two-sided t-test, error bars=SD. K Western blot of P-Rex1, ER and GAPDH in short-term fulvestrant and estrogen treated MCF-7 cells. Representative of 5 replicates. L Densitometry of P-Rex1 normalised to β-actin from n = 5 biological replicates, analysed by one-way ANOVA with Tukey’s multiple comparisons, error bars=SEM. M / N Multiplexed analysis of M pIGF1R and N pIR phosphorylation following treatment described in D . Analysed by two-way ANOVA with Bonferroni’s multiple comparisons. O Western blot of pIR/pIGF1R and β-actin in Fast and Endocrine Tolerant cells after 30 mins insulin. Representative of 3 replicates. P Western blot for P-Rex1 and GAPDH in Fast and Endocrine Tolerant cells expressing non-targeting (NT) and PREX1 shRNA, representative of n = 2 biological replicates. Q Quantitation of transwell migration assay of Fast and Endocrine Tolerant cells that express NT and PREX1 shRNA. Analysed by unpaired two-sided t-test from n = 3 biological replicates, error bars=SEM. R / S Correlation between PREX1 and EGFR in the (R) TCGA (RNAseq RSEM; n = 812 cancers) and S Metastatic Breast Cancer Project (RNAseq RSEM; n = 67 cancers). r=Spearman’s correlation. Orange line is least squares fit. Source data provided in Source Data file.

Journal: Nature Communications

Article Title: Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling

doi: 10.1038/s41467-026-70683-x

Figure Lengend Snippet: A Gene set enrichment analysis on Fast-growing compared to parental cells ( n = 288 genes) and Endocrine Tolerant resistant cells compared to parental cells ( n = 288 genes) using Curated.MSigDB. B / C Steiner Forest signalling network analysis in upregulated genes ( n = 288) of B Fast-growing and C Endocrine Tolerant cells. Node size indicates number of attached edges, with nodes with >8 in bold. Node colours: Brown=genes, light blue=phenotype, dark blue=protein complex, pink=protein family. D Multiplexed analysis of EGFR phosphorylation in: basal cells, 30 min 100 ng/mL EGF, 30 min 100 nM 17 β-estradiol, or 30 min serum stimulation. Analysed by two-way ANOVA with Bonferroni’s multiple comparison test from n = 3 biological replicates, error bars=SD. E Western blot of EGFR, pEGFR (Y1045) and β-actin in Fast and Endocrine Tolerant cells after 100 ng/mL EGF treatment for indicated times, representative of 3 biological replicates. F Multiplexed analysis of HER2 phosphorylation following treatment described in D . Analysed by two-way ANOVA with Bonferroni’s multiple comparison test. G Western blot of HER2, pHER2 (Y1221/1222) and β-actin in Fast and Endocrine Tolerant cells after 100 ng/mL EGF stimulation for indicated times, representative of 3 biological replicates. (H) PREX1 transcripts from scRNAseq analysis of MCF-7 cells treated for 48 hours with fulvestrant ( n = 340 cells), and in Fast-growing ( n = 578 cells) and Endocrine Tolerant ( n = 659 cells). I Western blot of P-Rex1, Rac1, Pak2 and β-actin in Fast and Endocrine Tolerant cells, representative of 3 biological replicates. J Densitometry of P-Rex1 normalised to β-actin from n = 3 biological replicates. Analysed by two-sided t-test, error bars=SD. K Western blot of P-Rex1, ER and GAPDH in short-term fulvestrant and estrogen treated MCF-7 cells. Representative of 5 replicates. L Densitometry of P-Rex1 normalised to β-actin from n = 5 biological replicates, analysed by one-way ANOVA with Tukey’s multiple comparisons, error bars=SEM. M / N Multiplexed analysis of M pIGF1R and N pIR phosphorylation following treatment described in D . Analysed by two-way ANOVA with Bonferroni’s multiple comparisons. O Western blot of pIR/pIGF1R and β-actin in Fast and Endocrine Tolerant cells after 30 mins insulin. Representative of 3 replicates. P Western blot for P-Rex1 and GAPDH in Fast and Endocrine Tolerant cells expressing non-targeting (NT) and PREX1 shRNA, representative of n = 2 biological replicates. Q Quantitation of transwell migration assay of Fast and Endocrine Tolerant cells that express NT and PREX1 shRNA. Analysed by unpaired two-sided t-test from n = 3 biological replicates, error bars=SEM. R / S Correlation between PREX1 and EGFR in the (R) TCGA (RNAseq RSEM; n = 812 cancers) and S Metastatic Breast Cancer Project (RNAseq RSEM; n = 67 cancers). r=Spearman’s correlation. Orange line is least squares fit. Source data provided in Source Data file.

Article Snippet: Primary antibodies were cyclin A (1:1000, #sc-239), cyclin D1 (1:500, #sc-20044), estrogen receptor-α (human) (1:500, #sc-543), β-actin (1:15,000, #sc-69879), and GAPDH (1:15,000, #sc-32233) from Santa Cruz Biotechnology; p21 (1:1000, #610234), and total Rb (1:500, #554136) from BD Biosciences; P-Rex1 (1:1000, #HPA001927) from Sigma-Aldrich; Rac1 (1:1000, #ARC03) from Cytoskeleton Inc; PAK2 (1:2000, #A4553) from AB Clonal; estrogen receptor-α (mouse) (1:1000, #ab32063) from Abcam; EGFR (1:1000, #H00001956-M02) from Abnova; pHER2 (Tyr1221/1222) (1:1000, #2243); pEGFR (Tyr1045) (1:1000, #2237), HER2 (1:1000, #2165) and pERK (Thr202/Tyr204) (1:1000, #9101) from Cell Signalling Technology; and pIR/IGF1R (Tyr1162/Tyr1163) (1:1000, #44-804 G) from Invitrogen.

Techniques: Phospho-proteomics, Comparison, Western Blot, Expressing, shRNA, Quantitation Assay, Transwell Migration Assay, RNA sequencing

A Schematic of spontaneous tumour development and dissemination in the MMTV-PyMT model. Expression of Rac1 (A_51_P513254), Prex1 (A_51_P348372) and Pak2 (A_51_P172323) in stages of MMTV-PyMT development ( GSE43566 ) of adenoma ( n = 5), carcinoma ( n = 6), dissemination ( n = 6) and metastases ( n = 5). Data analysed by one-way ANOVA with Tukey’s multiple comparisons. B Schematic of derivation of MMTV-PyMT Rac1-FRET biosensor mice with biosensor in active (blue) and inactive (red) conformations, and derivation of a chronic tamoxifen biosensor cell line. C MMTV-PyMT Rac1-FRET parental (PyMT) and chronic tamoxifen (PyMT-Tam) cell lines western blotted for ER, P-Rex1, Pak2 and Rac1. β-actin loading control is shown for each western blot. Representative of three replicates. D Densitometry of P-Rex1 expression normalised to β-actin from triplicate biological replicates, analysed by two-sided t-test, and error bars represent SEM. E Representative image of Rac1-FRET activity in MMTV-PyMT cells chronically treated with tamoxifen with matched parental control. Scale bar = 100 µm. F Quantitation of Rac1-FRET activity of cells in E . Triplicate biological replicates analysed by two-sided t-test; error bars represent SEM. G Schematic of MMTV-PyMT Rac1-FRET biosensor mouse with titanium optical imaging window implanted over a mammary tumour. H Tumour growth of control ( n = 11) and tamoxifen ( n = 9) treated MMTV-PyMT Rac1-FRET mice. Data analysed by two-way ANOVA with a mixed effect model. Error bars represent SEM. I Image of Rac1-FRET activity in control and tamoxifen treated mammary tumours, representative of three biological replicates. Scale bar = 50 µm. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling

doi: 10.1038/s41467-026-70683-x

Figure Lengend Snippet: A Schematic of spontaneous tumour development and dissemination in the MMTV-PyMT model. Expression of Rac1 (A_51_P513254), Prex1 (A_51_P348372) and Pak2 (A_51_P172323) in stages of MMTV-PyMT development ( GSE43566 ) of adenoma ( n = 5), carcinoma ( n = 6), dissemination ( n = 6) and metastases ( n = 5). Data analysed by one-way ANOVA with Tukey’s multiple comparisons. B Schematic of derivation of MMTV-PyMT Rac1-FRET biosensor mice with biosensor in active (blue) and inactive (red) conformations, and derivation of a chronic tamoxifen biosensor cell line. C MMTV-PyMT Rac1-FRET parental (PyMT) and chronic tamoxifen (PyMT-Tam) cell lines western blotted for ER, P-Rex1, Pak2 and Rac1. β-actin loading control is shown for each western blot. Representative of three replicates. D Densitometry of P-Rex1 expression normalised to β-actin from triplicate biological replicates, analysed by two-sided t-test, and error bars represent SEM. E Representative image of Rac1-FRET activity in MMTV-PyMT cells chronically treated with tamoxifen with matched parental control. Scale bar = 100 µm. F Quantitation of Rac1-FRET activity of cells in E . Triplicate biological replicates analysed by two-sided t-test; error bars represent SEM. G Schematic of MMTV-PyMT Rac1-FRET biosensor mouse with titanium optical imaging window implanted over a mammary tumour. H Tumour growth of control ( n = 11) and tamoxifen ( n = 9) treated MMTV-PyMT Rac1-FRET mice. Data analysed by two-way ANOVA with a mixed effect model. Error bars represent SEM. I Image of Rac1-FRET activity in control and tamoxifen treated mammary tumours, representative of three biological replicates. Scale bar = 50 µm. Source data are provided as a Source Data file.

Techniques: Expressing, Western Blot, Control, Activity Assay, Quantitation Assay, Optical Imaging

A The Rac1 pathway can be targeted by small molecule inhibitors; NSC23766, 1A-116, R-ketorolac. B / C Endocrine Tolerant and Fast-growing cells were treated with DMSO, 100 µM R-ketorolac, 25 µM NSC23766 and 6.25 µM 1A-116 for 1 week, and colony formation detected with 10% Diff Quik Stain 2. Colony formation (% colony area) ( n = 5 biological replicates) was quantitated using Image J. Data analysed by one-way ANOVA with multiple comparisons. Error bars are SEM. D / E Wound closure in Endocrine Tolerant and Fast-growing cells treated with DMSO, 100 µM R-ketorolac, 25 µM NSC23766 and 6.25 µM 1A-116 for 24 hours. Data ( n = 3 biological replicates) analysed by two-way repeated measure ANOVA for each treatment versus vehicle. Error bars are SEM, or smaller than the symbol. F Schematic of tamoxifen resistant MMTV-PyMT:Rac1-FRET biosensor mouse with titanium window implanted over mammary tumour to monitor Rac1-FRET activity after treatment with NSC23766 (4 mg/kg; intraperitoneal injection) or R-ketorolac (1 mg/kg; oral gavage). G Representative image of Rac1-FRET activity in tamoxifen resistant (TamR) MMTV-PyMT tumours treated with a single injection 4 mg/kg NSC23766, and single cell based temporal quantitation of Rac1-FRET activity of tumour. Data ( n = 4 mice measured at 0, 2, 24 h; n = 2 at 6 h) analysed by one-way ANOVA with Dunnett’s multiple comparison test, error bars are SEM. H Representative image of Rac1-FRET activity in tamoxifen resistant (TamR) MMTV-PyMT tumours treated with 1 mg/kg R-ketorolac and imaged for up to 96 hours, and single cell based temporal quantitation of Rac1-FRET activity of tumour. Data ( n = 4 mice measured at 0, 6, 24, 48, 72, 96 h; n = 2 at 2 h) analysed by one-way ANOVA with Dunnett’s multiple comparison test, error bars are SEM. Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling

doi: 10.1038/s41467-026-70683-x

Figure Lengend Snippet: A The Rac1 pathway can be targeted by small molecule inhibitors; NSC23766, 1A-116, R-ketorolac. B / C Endocrine Tolerant and Fast-growing cells were treated with DMSO, 100 µM R-ketorolac, 25 µM NSC23766 and 6.25 µM 1A-116 for 1 week, and colony formation detected with 10% Diff Quik Stain 2. Colony formation (% colony area) ( n = 5 biological replicates) was quantitated using Image J. Data analysed by one-way ANOVA with multiple comparisons. Error bars are SEM. D / E Wound closure in Endocrine Tolerant and Fast-growing cells treated with DMSO, 100 µM R-ketorolac, 25 µM NSC23766 and 6.25 µM 1A-116 for 24 hours. Data ( n = 3 biological replicates) analysed by two-way repeated measure ANOVA for each treatment versus vehicle. Error bars are SEM, or smaller than the symbol. F Schematic of tamoxifen resistant MMTV-PyMT:Rac1-FRET biosensor mouse with titanium window implanted over mammary tumour to monitor Rac1-FRET activity after treatment with NSC23766 (4 mg/kg; intraperitoneal injection) or R-ketorolac (1 mg/kg; oral gavage). G Representative image of Rac1-FRET activity in tamoxifen resistant (TamR) MMTV-PyMT tumours treated with a single injection 4 mg/kg NSC23766, and single cell based temporal quantitation of Rac1-FRET activity of tumour. Data ( n = 4 mice measured at 0, 2, 24 h; n = 2 at 6 h) analysed by one-way ANOVA with Dunnett’s multiple comparison test, error bars are SEM. H Representative image of Rac1-FRET activity in tamoxifen resistant (TamR) MMTV-PyMT tumours treated with 1 mg/kg R-ketorolac and imaged for up to 96 hours, and single cell based temporal quantitation of Rac1-FRET activity of tumour. Data ( n = 4 mice measured at 0, 6, 24, 48, 72, 96 h; n = 2 at 2 h) analysed by one-way ANOVA with Dunnett’s multiple comparison test, error bars are SEM. Source data are provided as a Source Data file.

Techniques: Diff-Quik, Staining, Activity Assay, Injection, Single Cell, Quantitation Assay, Comparison

Review

rac1 (Proteintech)

Structured Review

Images

Related Articles

Western Blot:

Saline:

Incubation:

Similar Products

Image Search Results